Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03475004 |
TitleStudy of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2018-03-23 |
地点
Colorado, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Bevacizumab, and Binimetinib |
标签
MSS/ MMRp
|
| NCT ID NCT03626922 |
TitleStudy of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | 阶段
第 1 阶段
|
Date Added 2018-08-13 |
地点
Florida, United States
Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT04991948 |
Title转移性结直肠癌患者在 CYAD-101 治疗后使用 FOLFOX 预处理的 Pembrolizumab 治疗研究 | 阶段
第 1 阶段
|
Date Added 2021-08-05 |
地点
Florida, United States
比利时 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
CYAD-101, FOLFOX, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05239741 |
TitleStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | 阶段
第三阶段
|
Date Added 2022-02-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT02608385 |
TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2015-11-18 |
地点
Illinois, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT06106308 |
TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | 阶段
第二阶段
|
Date Added 2023-10-30 |
地点
Arizona, United States
Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, FOLFIRI, FOLFOX, Onvansertib |
标签
MSS/ MMRp
|
| NCT ID NCT03155061 |
TitleStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2017-05-16 |
地点
日本
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
ONO-4538, ONO-4578, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT05215574 |
Title晚期或转移性实体瘤 NGM831 单药及与 Pembrolizumab 联合用药研究 | 阶段
第 1 阶段
|
Date Added 2022-01-31 |
地点
Arizona, United States
California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NGM831, NGM831 plus pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03476681 |
TitleNEO-201 在实体瘤中的研究扩增队列 | 阶段
Phase 1, Phase 2
|
Date Added 2018-03-26 |
地点
Maryland, United States
Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
NEO-201 in combination with pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06034860 |
TitleStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | 阶段
第 1 阶段
|
Date Added 2023-09-13 |
地点
California, United States
Indiana, United States Missouri, United States New York, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
MT-8421, Nivolumab, Opdivo |
标签
MSI-H/ MMRd
|
